Arthur A. Levin - Jan 12, 2023 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Scientific Officer
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Jan 12, 2023
Transactions value $
-$207,628
Form type
4
Date filed
1/17/2023, 07:50 PM
Previous filing
Jan 3, 2023
Next filing
Jan 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $12.4K +10K +751.88% $1.24* 11.3K Jan 12, 2023 Direct F1
transaction RNA Common Stock Sale -$220K -10K -88.26% $22.00 1.33K Jan 12, 2023 Direct F1, F2
holding RNA Common Stock 274K Jan 12, 2023 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -10K -11.31% $0.00 78.4K Jan 12, 2023 Common Stock 10K $1.24 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.04. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.